Pulmonary hypertension (PH) is a complex and often misunderstood condition. It is characterized by elevated pulmonary artery pressure, leading to right heart failure if left untreated. This article aims to provide a comprehensive understanding of PH, its pathophysiology, diagnosis, and management strategies.
PH is primarily a disease of the small pulmonary arteries, which become narrowed, obstructed, or destroyed. This leads to increased resistance to blood flow, resulting in elevated pulmonary artery pressure. The right ventricle, in response, undergoes hypertrophy and eventual failure. The underlying etiology can be idiopathic, familial, or associated with various systemic diseases.
Diagnosis is often challenging due to the non-specific nature of symptoms such as dyspnea, fatigue, and chest pain. Initial suspicion may arise from physical examination findings, electrocardiography, or chest radiography. However, echocardiography is the mainstay of diagnosis, providing estimates of pulmonary artery pressure and assessing right ventricular function. Definitive diagnosis requires right heart catheterization, demonstrating a mean pulmonary artery pressure of >25mmHg at rest.
Treatment of PH is multifaceted, aiming to alleviate symptoms, improve quality of life, and slow disease progression. Management strategies include general measures such as exercise, oxygen therapy, and anticoagulation. Pharmacological therapy includes endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogues. Severe cases may require lung transplantation.
In conclusion, PH is a complex disease process requiring a high index of suspicion for diagnosis. Understanding its pathophysiology is crucial for effective management. Treatment strategies are evolving with ongoing research, and a multidisciplinary approach is essential for optimal patient outcomes.
1.
Regular physical activity before cancer diagnosis may lower progression and death risks
2.
Medication Self-Injection Embraced by Breast Cancer Patients
3.
Financial hardship for cancer survivors due to high-cost immunotherapies, especially for blood cancer patients
4.
FDA Advisors Split on Regimens for Breast, Prostate Cancers
5.
ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs
1.
RDW-CV vs. MCV: Knowing the Difference Can Help You Better Understand Your Health
2.
Clinical Pathways in Hematology in Clinical Decision-Making
3.
Immune Surveillance Screening for Early Cancer Risk Detection
4.
Unlocking the Mysteries of Lymphoblastic Lymphoma: A Journey Into the Unknown
5.
AI-Driven Digital Pathology in Oncology: From Histology Images to Predictive Treatment Biomarkers
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
How Advances in Cancer Research Are Improving Treatment Options
2.
Navigating the Complexities of Ph Negative ALL - Part II
3.
Signs and Symptoms of Leukemia
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation